34.35
-2.81
(-7.56%)
May 17 - Close
EBR data delayed by 15 mins - Disclaimer
Currency in EUR
| Range | 34.31 - 36.80 |
| 52 week | 17.10 - 47.82 |
| Open | 36.00 |
| Vol / Avg. | 718,154.00/790.00 |
| Mkt cap | 1,231.80M |
| P/E | 37.25 |
| Div/yield | - |
| EPS | 0.92 |
| Shares | 35.86M |
| Beta | - |
| Inst. own | - |
Events
May 22, 2013
ThromboGenics NV at UBS Global Healthcare Conference
- 6:30pm CEST -
May 16, 2013
Q1 2013 ThromboGenics NV Business Update
May 7, 2013
ThromboGenics NV Annual Shareholder Meeting
Mar 19, 2013
ThromboGenics NV at KBC Securities Healthcare Conference
|
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | -122576.20% | 40.50% |
| Operating margin | -124676.20% | 38.75% |
| EBITD margin | - | 39.66% |
| Return on average assets | -20.63% | 16.52% |
| Return on average equity | -21.46% | 17.58% |
| Employees | 134 | - |
| Carbon Disclosure Rating | - | - |
Address
Gaston Geenslaan 1
LEUVEN (LOUVAIN), 3001
Belgium
+32-16-751310 (Phone)
+32-16-751311 (Fax)
LEUVEN (LOUVAIN), 3001
Belgium
+32-16-751310 (Phone)
+32-16-751311 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Thrombogenics NV is a Belgium-based biopharmaceutical company focused on the discovery and development of medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead drug candidateocriplasmin (microplasmin), completed two phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (sVMA). The TN-402 (Anti-factor VIII) drug candidate against deep vein thrombosis and atrial fibrillation is in phase I of the clinical trials. The TB-403 anticancer agent was licensed to F. Hoffmann La Roche AG which will subject it to phase II clinical trials. The Staphylokinase candidate against Acute myocardial infarction (AMI) successfully completed phase II clinical trials. The Company has its Branch in Ireland and also subsidiary in the United States.
Officers and directors
| Patrik De Haes M.D. | Chief Executive Officer, Executive Director, Representative of ViBio BVBA | |
| Chris Buyse | Chief Financial Officer, Executive Director | |
| Koen Kas | Chief Scientific Officer - Oncology | |
| Ram Palanki | Global Head of Marketing | |
| Laurence Raemdonck | Head of Human Resources | |
| Andy De Deene | Head of Program Management | |
| Aniz Girach | Head of Clinical Ophthalmology | |
| Christian Jaeggi | Head of Country Operations EU/ROW | |
| David Pearson | Head of Country Operations United States | |
| Desire Collen M.D., Ph.D. | Non-Executive Chairman of the Board, Representative of Patcobel NV |